目的探讨血清肿瘤型M2丙酮酸激酶(tumor M2 pyruvatekinase,Tu M2-PK)在胃癌诊断中的价值。方法胃癌患者306例(胃癌组),胃良性病变患者96例(胃良性病变组)及64例健康体检者(对照组),采用ELISA法检测3组血清Tu M2-PK水平,以Tu M2-PK>15 U/ml为阳性判定标准,分析胃癌组血清Tu M2-PK阳性率与临床参数的的关系。结果胃癌组血清Tu M2-PK水平[(26.23±5.36)U/ml]明显高于胃良性病变组[(18.52±3.66)U/ml L]及对照组[(17.68±4.02)U/ml](P<0.05),胃良性病变组与对照组比较差异无统计学意义(P>0.05);胃癌组血清Tu M2-PK阳性率在肿瘤分化程度、淋巴结转移、临床分期上差异有统计学意义(P<0.05)。结论血清Tu M2-PK在判定胃癌分化程度、淋巴结转移、临床分期上有一定价值,有助于胃癌的诊断。 Objective To investigate the value of serum tumor M2 pyruvate kinase (Tu M2-PK) in the diagnosis of gastric cancer. Methods The serum levels of Tu M2-PK in 306 gastric cancer patients, 96 gastric benign lesion patients (benign gastric lesions group) and 64 healthy volunteers (control group) were measured by ELISA. The serum levels of Tu M2- PK> 15 U / ml as the positive criterion, the relationship between the positive rate of Tu M2-PK in gastric cancer group and clinical parameters was analyzed. Results The serum level of Tu M2-PK in gastric cancer group was significantly higher than that in benign gastric lesion group ([(26.23 ± 5.36) U / ml] [(18.52 ± 3.66) U / ml L] and [17.68 ± 4.02 U / ml] (P0.05) .There was no significant difference between gastric benign lesion group and control group (P0.05). The positive rate of Tu M2-PK in gastric cancer group was significantly different between tumor differentiation, lymph node metastasis and clinical stage (P <0.05). Conclusion Serum Tu M2-PK has certain value in determining the degree of gastric cancer differentiation, lymph node metastasis and clinical stage, which is helpful for the diagnosis of gastric cancer.